BEGIN:VCALENDAR VERSION:2.0 PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:KESHO X-ORIGINAL-URL:https://kesho-kenya.org X-WR-CALDESC:Events for KESHO REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Africa/Nairobi BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0300 TZNAME:EAT DTSTART:20180101T000000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20201021T190000 DTEND;TZID=Africa/Nairobi:20201021T203000 DTSTAMP:20260427T054237 CREATED:20210813T135003Z LAST-MODIFIED:20211024T154040Z UID:5888-1603306800-1603312200@kesho-kenya.org SUMMARY:Breast Cancer Early Diagnosis and Screening Part 2 DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Vera Manduku Presenters: \n\nDr. Mary Nyangasi\, Head of Division\, National Cancer Control Program\, Ministry of Health\, Kenya\nDr. Miriam Mutebi\, Consultant\, Breast Surgical Oncologist\, Aga Khan University Hospital\n\nThe ministry of health is commemorating the annual national breast cancer awareness month 2020 by giving hope and saving the lives of breast cancer patients. Globally\, cancer is a major cause of death\, accounting for 1 out of 6 deaths annually. Over 70% of deaths occur in low and middle-income countries\, where breast cancer accounts for 6.6% of all cancer deaths. In Kenya\, cancer is the second leading cause of death from non-communicable diseases\, accounting for 7% of overall mortality. Breast cancer is the third leading cause of death after esophageal and cervical cancers. Good prognosis is associated with timely screening and early detection\, followed by timely treatment. Unfortunately\, awareness and uptake of screening services remain low in Kenya. Consequently\, 70% of breast cancer cases are diagnosed in advanced stages. Since survival of breast cancer patients is highly dependent on the stage of diagnosis\, a low survival rate is observed in stage IV patients. To support the management of breast cancer\, the ministry of health\, Kenya has put infrastructure for screening mammography in all the 47 County Referral Hospitals. In addition\, the ministry has provided national cancer screening guidelines (2018) to guide an organized and unified approach for screening priority cancers including cervix\, breast\, colorectal\, prostate\, and retinoblastoma.  Mammography is the recommended method of screening for women in the average-risk population\, and the only screening modality shown to reduce breast cancer mortality. Previous studies have shown that screening mammography helps with the early detection of cancer and greatly reduces breast cancer deaths for women aged 40-74 years as well as those above 74 years. However\, mammography is very costly and is only recommended for countries with good health infrastructure that can afford long-term programs. Other early detection techniques include a clinical breast examination\, ultrasound\, monthly breast self-examination\, and breast self-awareness. Breast cancer management in low and middle-income countries is complicated by poor health systems\, poverty\, and retrogressive cultural practices. In these countries\, awareness of early signs and symptoms and screening by clinical breast examinations are recommended for the early detection of breast cancer. In Kenya\, screening is mainly opportunistic\, mainly due to challenges associated with lack of equipment\, radiologists\, and radiology personnel. The risk of breast cancer is stratified into two: the average-risk population\, accounting for 80%\, while the high-risk population (20%). While there is a need for risk reduction strategies\, the risks involved in mammography are non-lethal; hence screening benefits outweigh the risks involved. Some of the risks include recall for additional imaging\, needle biopsy\, false positives\, anxiety\, and over-diagnosis. Lifestyle and environmental factors can have an impact on breast cancer risk. Some of the risk reduction measures include maintaining a healthy weight\, exercising regularly\, and limiting the amount of alcohol.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/breast-cancer-early-diagnosis-and-screening/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_163658.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20201013T190000 DTEND;TZID=Africa/Nairobi:20201013T203000 DTSTAMP:20260427T054237 CREATED:20210813T134000Z LAST-MODIFIED:20211024T154048Z UID:5883-1602615600-1602621000@kesho-kenya.org SUMMARY:Childhood Cancers and Early Detection DESCRIPTION:[vc_row][vc_column][vc_column_text] \nModerator: Dr. Sitna Mwanzi \nPresenters: \n\nDr. Valerian Mwenda\, Medical epidemiologist\, Lead Cancer registration\, Monitoring\, Evaluation and Research\, Division of National Cancer Control Program\, Ministry of Health.\nDr. Doreen Karimi Mutua\, Paediatric\, hematologist/ oncologist\, Gertrude’s Children’s Hospital\, Childhood Cancer Initiative\n\nChildhood cancer is becoming a public health crisis in the developing world. In high-income countries\, the childhood cancer prevalence is only 20%\, with up to 80% cure rates. Low and middle-income countries account for 80% of all new cancer cases and less than 20% survival rates. In 2018\, 3000 new cases of childhood cancers were reported in Kenya\, where the survival rate is less than 19-30%. The low survival rate is attributed to the late presentation of patients\, lack of knowledge and awareness of symptoms and signs among health care workers\, weak referral systems\, few cancer diagnostic and treatment centers\, cultural beliefs and myths\, and financial constraints. To overcome these challenges\, there is a need to raise awareness among caregivers and health care workers on early warning signs\, encourage health-seeking behavior among Kenyans\, strengthen referral systems to avoid time wastage\, equip and train staff to diagnose and treat\, adopt evidence-based protocols for the treatment of cancer patients\, maintain data on the outcomes\, and use it for treatment and resource planning. The global initiative for childhood cancer target for 2030 is to realize a double cure rate\, ensuring at least 60% survival for children with cancer globally\, and reducing suffering for all. To achieve this\, efforts are being put in place to increase the capacity of countries to provide quality services for children with cancer\, and to increase the prioritization of childhood cancer at the global\, regional\, and national levels. According to Kenya National Cancer Registry\, the most common childhood cancers are Leukemia\, Retinoblastoma\, Renal\, Lymphoma\, and Central Nervous System. The risk factors are majorly unknown\, though exposure to ionizing radiation and infectious agents has been associated with some cancers. The goal of the Kenya Cancer Policy is to provide a multi-sectoral framework to comprehensively address the cancer burden in the country. The national cancer control strategy (2017-2022) aims to optimize treatment and palliative care for childhood cancers. The national cancer screening guidelines guide early diagnosis while the national cancer treatment protocols guide treatment.  Barriers to effective childhood cancer control include a low level of awareness\, low index of suspicion among the caregivers\, poor referral systems\, and inadequate access to palliative care. Other system challenges include poor access to health care\, lack of finances\, and inadequate surveillance and tracking systems.  To counter these challenges the ministry of health Kenya is increasing advocacy\, training among the health care providers\, and universal health coverage.  Early detection of childhood cancer is key to improved survivorship and health outcomes\, timely access to treatment and care\, lower intensity of treatment\, cost-saving for families and health systems\, and a lower burden of short and long-term toxicity. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n  \n  \n  \n  \n\n\n  \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/childhood-cancers-and-early-detection/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_163619.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20201008T191500 DTEND;TZID=Africa/Nairobi:20201008T203000 DTSTAMP:20260427T054237 CREATED:20210812T095227Z LAST-MODIFIED:20211024T153727Z UID:5878-1602184500-1602189000@kesho-kenya.org SUMMARY:The Role of Immunotherapy in Cancer Management DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Miriam Mutebi \nSponsor: Beacon \nPresenters: \n\nProf. Asim Jamal Shaikh\, Associate professor of Medicine\, Consultant Medical Oncologist\, Aga Khan Hospital\, Nairobi.\n\nImmunotherapy is a type of cancer treatment that boosts the body’s natural defenses to fight cancer cells. It uses substances made by the body or in a laboratory to improve how your immune system works to find and destroy cancer cells. Traditional therapies such as surgery\, radiation\, and cytotoxic/targeted therapy target tumor cells\, while immunotherapy harnesses the body’s immune system to fight diseases. Anti-tumor immunotherapy includes cancer vaccines that educate T cells to better recognize and kill the pre-existing tumor. Adoptive immunotherapy activates and increases T cell numbers to better kill tumor cells. Immunomodulation uses drugs or antibodies to either increase stimulation or to overcome immune inhibition. Many tumors escape the immune response by creating an immunosuppressive microenvironment that prevents an effective anti-tumor response\, mainly through the involvement of the immune checkpoints located in the central or peripheral regions. The immune checkpoints PD-L1 binds to PD-1 and inhibits T cell killing of tumor cell\, therefore\, blocking PD-L1 or PD-1 allows T cell killing of tumor cells\, while CTLA4 regulate the early phase of activation of naïve and memory T cells in response to T cell receptor (TCR) stimulation by peptides presented by MHC ligands expressed by antigen-presenting and processing cells. Its upregulation prevents normal T cell activation. Several checkpoint inhibitors with FDA approval are in clinical use and have proven to be highly effective in the treatment of relapsed\, progressive solid cancers\, with relatively mild but distinct safety profiles. Some immune checkpoint inhibitors available in Kenya\, are quite costly\, and hence National Hospital Insurance Fund (NHIF) is too little to cover for this treatment. Aga Khan is building capacity for PD-L1 analysis\, an immunohistochemistry test\, in addition to next-generation sequencing. More data is required on the safety of immunotherapy and its use on immunocompromised individuals e.g. HIV\, and those with autoimmune diseases\, Since several clinical trials\, are in progress; more new indications are likely to emerge.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/the-role-of-immunotherapy-in-cancer-management/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210812_124901.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200929T190000 DTEND;TZID=Africa/Nairobi:20200929T203000 DTSTAMP:20260427T054237 CREATED:20210604T163946Z LAST-MODIFIED:20211024T154727Z UID:5302-1601406000-1601411400@kesho-kenya.org SUMMARY:Management of Hormone Receptor Positive Breast Cancer DESCRIPTION:[vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/management-of-hormone-receptor-positive-breast-cancer/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/image_2021-06-04_193725.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200915T191500 DTEND;TZID=Africa/Nairobi:20200915T203000 DTSTAMP:20260427T054237 CREATED:20210817T111009Z LAST-MODIFIED:20211024T154755Z UID:5918-1600197300-1600201800@kesho-kenya.org SUMMARY:Management of Neuroendocrine Tumors DESCRIPTION:[vc_row][vc_column][vc_column_text] \n\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Moderator: Dr. Sitna Mwanzi \nSponsor: Novartis \nPresenters: \n\nNjoki Njiraini\, a consultant clinical oncologist based at the Cancer Centre in Kenyatta University Teaching Research and Referral Hospital.\n\nNeuroendocrine Neoplasms arise from diffuse neuroendocrine cells in the body and are broadly divided into well-differentiated neuroendocrine tumors (NETs)\, including the sporadic small intestine\, pancreatic\, thorax\, and thymus NETs\, and poorly differentiated neuroendocrine carcinomas (NECs)\, classified based on differentiation\, Ki67 levels\, and mitotic figures. NETs arise from neuroendocrine cells throughout the body. There has been increasing incidence over the last 15 years\, with a male preponderance and a more adverse outcome. Diagnosis is mainly through histology and immunohistochemistry. Staging for NECs is mainly by adenocarcinoma staging system\, which mainly involves imaging through CT scan\, MRI\, Contrast-Enhanced USS\, endoscopic USS\, and functional imaging. Treatment is dependent on TNM staging and grading of the disease and includes surgery\, somatostatin analogs\, hepatic-directed therapies\, and chemotherapeutics. For a patient with carcinoid syndrome\, the short-acting octreotide can be considered first\, while waiting for long-acting octreotide to act. Locally\, therapies are available in 20 mg from Novartis retailing at 68000 Kenya shillings\, but 30mg are also available in the market through other distributors. The toxicity profiles should be put into consideration e.g. diarrhea\, although sometimes it’s difficult to differentiate drugs’ side effects from the initial tumor signs. Neuroendocrine carcinomas are classified as small or large cells and mostly the patients have poor outcomes. There is a need to improve imaging and multidisciplinary teams to share local experiences of neuroendocrine patients.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n\n\n\n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/management-of-neuroendocrine-tumors-2/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_171140.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200908T191500 DTEND;TZID=Africa/Nairobi:20200908T203000 DTSTAMP:20260427T054237 CREATED:20210817T105953Z LAST-MODIFIED:20211024T154816Z UID:5914-1599592500-1599597000@kesho-kenya.org SUMMARY:Management of Iron Overload DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Paresh Dave \nSponsor: Novartis \nPresenters: \n\nPeter Oyiro\, Medical Oncologist Kenyatta National Hospital Teaching and Referral Hospital\n\nIron overload is a poly etiologic condition characterized by a moderate to severe increase in the body iron that has or will have negative effects secondary to iron deposition in tissues or body organs. It may be hereditary or acquired. It is important to detect the disease before organ damage occurs. Iron overload affects overall survival partly due to the underlying biology of the disease but also because of the sequelae of iron overload\, including cardiomyopathy\, cardiac events\, liver disease\, and the development of diabetes. For patients with higher serum ferritin levels\, the 100-day post-transplant mortality is worse with inferior overall survival (OS) and a higher rate of graft vs host disease.  Therefore\, iron chelation therapy can improve OS and is effective at reducing serum ferritin levels\, cardiac events\, and diabetes in patients with blood-transfusion-related iron overload. Compliance is highly encouraged to realize successful treatment. The safety profile of each chelator should be evaluated before the initiation of treatment. Patients receiving chemotherapy and who have a drop in blood count parameters require evaluation to find out the causes. Iron studies are required to generate more data. Iron supplementary can be toxic. Patients with severe organ dysfunction can have a combination of iron chelation therapy.  Ferritin levels should be done every 3 months.  Iron chelation OS is not contraindicated in HIV patients with evidence of iron overload.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/management-of-iron-overload/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_170945.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200827T070000 DTEND;TZID=Africa/Nairobi:20200827T203000 DTSTAMP:20260427T054237 CREATED:20210604T162505Z LAST-MODIFIED:20211024T154948Z UID:5294-1598511600-1598560200@kesho-kenya.org SUMMARY:Cancer and Thrombosis Current Perspective DESCRIPTION:[vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/cancer-and-thrombosis-current-perspective/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/06/image_2021-06-04_193129.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200811T191500 DTEND;TZID=Africa/Nairobi:20200811T201500 DTSTAMP:20260427T054237 CREATED:20210813T143324Z LAST-MODIFIED:20250622T142511Z UID:5898-1597173300-1597176900@kesho-kenya.org SUMMARY:Emerging Therapies in Hodgkin's Lymphoma Management - Treatment Beyond The Basics DESCRIPTION:[vc_row][vc_column][vc_column_text] \nModerator: Dr. Miriam Mutebi \nSponsor: Takeda\, a pharmaceutical company with a patient assistance program for Hodgkin’s lymphoma in Kenya. \nPresenters: \n\nDr. Anna Sureda\, Head of the Clinical Hematology Department and the Stem Cell Transplantation program of Institut Catala d’Oncologia – Hospitalet\, Barcelona\n\nHodgkin’s lymphoma (HL) is one of the most curable hematological malignancies with first-line treatment\, which is a combination of radiotherapy and chemotherapy. Autologous hematopoietic stem cell transplantation (auto-HCT) is the standard therapy for HL patients relapsing after first-line chemotherapy. The use of allogeneic stem cell transplantation (ASCT) has improved the overall survival (OS) of patients over time.  To improve the landscape of chemotherapy treatment for refractory disease\, a new drug\, Brentuximab vedotin\, has been introduced. This drug is an antibody-drug conjugate (ADC) consisting of 3 components; it binds to CD30 forming a complex that is internalized and traffics to the lysosome. The drug was granted accelerated approval by the US FDA in 2011.  The European Medicines Agency (EMA) approved this drug in 2012 for the treatment of adult patients with relapsed or refractory CD30+ HL\, anaplastic large cell lymphoma\, and those at increased risk of relapse or progression following ASCT. The efficacy reported as median observation time from the first dose at study closure was 35.1 months (1.8-72.9). Studies revealed that Brentuximab vedotin and ESHAP are highly effective as second-line therapy for Hodgkin’s patients. Brentuximab vedotin was the first targeted therapy that was tested in patients with relapsed/refractory HL. It was very effective as a single drug in patients that relapse or progress after auto-HCT. Brentuximab vedotin is able to potentially increase the number of patients that are candidates to auto-HCT. It improves progression-free survival (PFS) in those patients with a high risk of relapse after auto-HCT when used as a consolidation strategy. It has demonstrated an adequate and safe toxicity profile\, even in HIV-positive patients with HL. Brentuximab vedotin is being used in other settings with very interesting results (RR setting in combination with chemotherapy\, first line). However\, the cost of the treatment in Kenya is quite high; a single vial costs Kshs. 330\,000. A patient assistance program in partnership with Takeda is helping patients in Kenya who cannot afford to pay\, to complete their treatment. Although this program is run in private hospitals\, physicians seeing patients at public facilities can refer the patients to the private facilities for assistance\, but continue to follow up on the patients. \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column] \n \n Webinar Recording \n \n \n [vc_column_text] \n[vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/emerging-therapies-in-hodgkins-lymphoma-management-treatment-beyond-the-basics/ CATEGORIES:CME 2020,Webinar Recording Available ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2021/08/IMG_20210813_170809.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20200730T191500 DTEND;TZID=Africa/Nairobi:20200730T203000 DTSTAMP:20260427T054237 CREATED:20210810T101728Z LAST-MODIFIED:20250622T142511Z UID:5839-1596136500-1596141000@kesho-kenya.org SUMMARY:Ovarian Cancer\, The Good\, The Bad\, And The Ugly DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr. Andrew Odhiambo\, Consultant Medical Oncologist & Lecturer\, University of Nairobi \nSponsor: Merck \nPresenters: \n\nDr. Benjamin Odongo Elly\, Gynecologic Oncologist at Moi Teaching and Referral University.\n\nMoi Teaching and Referral Hospital (MTRH) cancer center offers a holistic approach to cancer treatment. Germ cell tumors account for 10-115% of all ovarian tumors and affect young females of reproductive age. They are very chemosensitive hence are curable\, using fertility-sparing surgery. Stromal tumors account for 3-5% of all ovarian tumors and affect women of all ages. These tumors are diagnosed early and are histologically low-grade\, with a good prognosis\, when treated with surgery\,  followed by adjuvant treatment. However\, some tumors are aggressive and lethal. Epithelial tumors represent 80-85% of all ovarian tumors. They have a poor prognosis and are always detected late. Warning signs include abdominal bloating\, abdominal/pelvic pain\, bowel/bladder symptoms\, and irregular vaginal bleeding. Prevention of ovarian cancer is by avoidance of risk factors and prophylactic surgery in high-risk women. There is currently no good screening test for the general population. Diagnosis is by appropriate physical examination\, pelvic/transvaginal ultrasound\, tumor markers\, and CT scan. The majority of patients are diagnosed with advanced-stage disease (stage III or IV) leading to poor overall 5-year survival. However\, patients are living longer with the disease due to advances in surgery and chemotherapy treatment. As a country\, there is a need to improve the early diagnosis of ovarian cancer through advocacy\, patient education\, human resource\, training capacity building\, and availing resources to the health care facilities.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"] \n Access our Membership Page \n [/vc_column_inner][vc_column_inner width="1/3"] \n Fill in the Membership Form \n [/vc_column_inner][vc_column_inner width="1/3"] \n Access Membership Portal \n [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/ovarian-cancer-the-good-the-bad-and-the-ugly/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2020,Webinar Recording Available END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20191121T200000 DTEND;TZID=Africa/Nairobi:20191121T220000 DTSTAMP:20260427T054237 CREATED:20210420T152935Z LAST-MODIFIED:20250622T142511Z UID:4731-1574366400-1574373600@kesho-kenya.org SUMMARY:TOPIC: Management of Brain Tumors DESCRIPTION:[vc_row][vc_column][vc_column_text] \nFinally\, KESHO partnered with the Neurological Society of Kenya to discuss the management of brain tumors with a stimulating surgical perspective from Dr Edwin Mogere Neurosurgeon and an in-depth discussion of management of medical symptoms from brain tumors by Dr Judy Kwasa Neurologist. \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-management-of-brain-tumors/ LOCATION:Crowne Plaza Hotel CATEGORIES:CME 2019,Webinar Recording Available END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190829T200000 DTEND;TZID=Africa/Nairobi:20190829T220000 DTSTAMP:20260427T054237 CREATED:20210420T153545Z LAST-MODIFIED:20250622T142511Z UID:4736-1567108800-1567116000@kesho-kenya.org SUMMARY:TOPIC: BCR-ABL and OSTEOGENIC SARCOMA DESCRIPTION:[vc_row][vc_column][vc_column_text]We took a well-deserved break in July 2019 and came back in August for a mixed presentation on CML and osteogenic sarcoma from Prof Nicholas Abinya Medical Oncologist and Dr Mohammed Ezzi Medical Oncologist. The outcome for patients with CML has significantly improved with TKI therapies\, yet challenges persist in adequate monitoring which is expensive. The lack of co-ordinated multidisciplinary care needed for osteogenic sarcoma led to many lost to follow up and incomplete treatments with poor outcomes. MDTs prior to treatment is a potential strategy for reversing this trend.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-bcr-abl-and-osteogenic-sarcoma/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190829T170000 DTEND;TZID=Africa/Nairobi:20190829T200000 DTSTAMP:20260427T054237 CREATED:20210420T153328Z LAST-MODIFIED:20250622T142510Z UID:4734-1567098000-1567108800@kesho-kenya.org SUMMARY:SSA Breast Cancer DESCRIPTION:[vc_row][vc_column][vc_column_text]Another busy month for us with three meetings in October. First off\, Prof Asim Jamal Medical Oncologist gave an excellent overview of presentation\, diagnosis and management of neuroendocrine tumors which are not as rare as originally felt. KESHO then partnered with Pathologists Lancet Kenya to discuss molecular diagnostics in hemato-oncology. Speakers from France and our very own experts deliberated on the changing landscape of hemato-oncology and what is practical in our setting. Finally\, a multidisciplinary webinar session on breast cancer concluded our sessions for the month in recognition of the Breast Cancer Awareness month\, with presentations from Dr. Gladwell Kiarie Medical Oncologist\, Dr. Fred Okuku Medical Oncologist\, Dr. Aba Anoa Scott Radiation/Clinical Oncologist and Prof. Ronald Wasike Breast Surgeon.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/ssa-breast-cancer/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019 END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190627T110000 DTEND;TZID=Africa/Nairobi:20190627T200000 DTSTAMP:20260427T054237 CREATED:20210420T154157Z LAST-MODIFIED:20250622T142511Z UID:4738-1561633200-1561665600@kesho-kenya.org SUMMARY:TOPIC: Paediatric Malignancies; Optimising Care In Acute Leukaemia DESCRIPTION:[vc_row][vc_column][vc_column_text]We directed our focus on hematology and this time we concentrated on pediatric malignancies. Dr. Jamila Rajab Consultant Haematologist\, Dr. Grace Mbatia Paediatric Oncologist and Dr Festus Njuguna Paediatric Oncologist. We got a glimpse on the myriad challenges our colleagues in hematology face in the management of pediatric hematological malignancies including complicated regimens\, high rate of drop outs and poor supportive care. The outcome was to continue in the process of development of national treatment protocols that can be used which can also help in comparing treatment outcomes in the different settings.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-paediatric-malignancies-optimising-care-in-acute-leukaemia/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190523T200000 DTEND;TZID=Africa/Nairobi:20190523T220000 DTSTAMP:20260427T054237 CREATED:20210420T154450Z LAST-MODIFIED:20250622T142511Z UID:4740-1558641600-1558648800@kesho-kenya.org SUMMARY:TOPIC: Colon Cancer; A Multidisciplinary Approach DESCRIPTION:[vc_row][vc_column][vc_column_text]This was a busy month for our members with three educational events! Dr. Joe Ruturi Cardiothoracic Surgeon and Dr. Solomon Mutua Clinical Oncologist started off the month with discussions on upper GI cancers\, in particular esophageal cancer. KESHO collaborated with ROCHE in their sub-Saharan MPANGO two-day meeting in which many of our members were speakers. The conference focused on triple negative and HER2 breast cancer\, colon and lung cancer. The month ended with an excellent multidisciplinary meeting on colon cancer spearheaded by our very own past Chair\, Dr. Gladwell Kiarie Medical Oncologist and Dr. Rajendra Chauhan Surgical Oncologist. There was a lot of input from our surgical and radiation colleagues.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-colon-cancer-a-multidisciplinary-approach/ LOCATION:Radisson Blu\, Upperhill Nairobi\, Nairobi\, Nairobi\, 00100\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190427T200000 DTEND;TZID=Africa/Nairobi:20190427T220000 DTSTAMP:20260427T054237 CREATED:20210420T155152Z LAST-MODIFIED:20250622T142511Z UID:4743-1556395200-1556402400@kesho-kenya.org SUMMARY:TOPIC: HIV Malignancies Symposium DESCRIPTION:[vc_row][vc_column][vc_column_text]KESHO held a half-day joint symposium with the HIV Clinicians Society discussing the various aspects of HIV related malignancies and how we can better co-manage these patients for improved outcomes. More local research is needed to understand the true prevalence of a co-diagnosis of HIV and cancer and in particular non-AIDS defining malignancies.[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-hiv-malignancies-symposium/ LOCATION:Movenpick Hotel\, Nairobi CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190328T000000 DTEND;TZID=Africa/Nairobi:20190328T235959 DTSTAMP:20260427T054237 CREATED:20210421T195426Z LAST-MODIFIED:20250622T142510Z UID:4784-1553731200-1553817599@kesho-kenya.org SUMMARY:Topic: Acute Leukaemia DESCRIPTION:[vc_row][vc_column][vc_column_text] \nProf. Nicholas Abinya Medical Oncologist and Dr. Anne Mwirigi Haematologist gave stimulating perspectives on their care of patients with AML in a public versus a private setting. This led to discussions on collaborations on improving standards of care in our country and in particular with regards to supportive care and financing. KESHO is now engaging with NHIF and the NCCP to outline a treatment package for these patients that factor other costs apart from direct chemotherapy drugs. \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-acute-leukaemia/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190228T000000 DTEND;TZID=Africa/Nairobi:20190228T235959 DTSTAMP:20260427T054237 CREATED:20210421T200249Z LAST-MODIFIED:20250622T142510Z UID:4786-1551312000-1551398399@kesho-kenya.org SUMMARY:Topic: Updates on Recently Launched Cancer Screening Guidelines DESCRIPTION:[vc_row][vc_column][vc_column_text]In line with the launch of the Kenya Cancer Screening guidelines\, Dr Andrew Odhiambo Medical Oncologist and Dr Primus Ochieng Clinical Oncologist presented on their perspectives on the new guidelines and their experience in other settings outside of Kenya. The Screening Guidelines is as shown below: \n\n\n\n PDF Loading...\n \n \n \n \n\n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-updates-on-recently-launched-cancer-screening-guidelines/ CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20190131T000000 DTEND;TZID=Africa/Nairobi:20190131T235959 DTSTAMP:20260427T054237 CREATED:20210421T200621Z LAST-MODIFIED:20250622T142510Z UID:4791-1548892800-1548979199@kesho-kenya.org SUMMARY:Topic: Updates in Breast Cancer Management DESCRIPTION:[vc_row][vc_column][vc_column_text] \nWe started off the year discussing the most common cancer in women in Kenya and worldwide with two presentations. Dr Miriam Mutebi Surgical Oncologist gave an update on the surgical techniques of breast cancer management and Dr Njoki Njiriani Clinical Oncologist talking on new therapies for advanced hormone positive breast cancer \n[/vc_column_text][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/topic-updates-in-breast-cancer-management/ LOCATION:Sarova Panafric Hotel\, Nairobi\, Kenya.\, Kenya CATEGORIES:CME 2019,Continuing Medical Education (CME) END:VEVENT END:VCALENDAR